Numerous umbrella protocol studies are ongoing, one example being the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), which is investigating the use of targeted therapy in patients with resectable adenocarcinoma of the lung with EGFR mutation or ALK translocation after completion of standard therapy [171]. Here, EGFR is linked to lung carcinoma.